Navigation Links
ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Date:7/29/2010

x patients who stopped all treatment at Week 24 were part of an investigation of response-guided treatment duration for ANA598 in which patients who had achieved undetectable levels of virus (<15 IU/mL) at Weeks 4 and 12 were randomized 1:1 to stop all treatment at Week 24 or Week 48.  In addition to the six patients who stopped treatment at Week 24, six patients in the 200 mg bid arm are continuing to receive SOC alone through Week 48 for comparison purposes.  Additionally, 14 patients from the ANA598 400 mg bid arm and 4 patients from the control arm (receiving placebo plus SOC) met the stopping criteria and have been randomized to stop all treatment at Week 24 or 48.  The initial post-treatment results from these latter arms are expected later this year for those patients who stopped therapy at Week 24.

Conference Call Webcast and Slides

Anadys will hold a conference call and webcast today, Thursday, July 29, 2010 at 8:30 a.m. Eastern Daylight Time to discuss the post-treatment results from the ongoing Phase II combination study and Anadys' second quarter 2010 financial results   A live webcast of the call, including accompanying slides, will be available online at www.anadyspharma.com.  A telephone replay with slides will also be available approximately one hour after completion of the call.  To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 28631163.  The webcast and telephone replay will be available through August 12, 2010.

Phase II Combination Study


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
11. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and ... AZN ) today announced that they have entered into ... preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, ... VEGF Receptor 2 antiangiogenic cancer medicine. The planned study ... with advanced solid tumors. The Phase I ...
(Date:5/29/2015)... , May 29, 2015 Educating ... of the Association for the Advancement of Wound ... With support from AAWC,s corporate partners, the ... Portal on the AAWC website at ... wound care pathway with links to various CME/CEU ...
(Date:5/28/2015)... HOUSTON , May 28, 2015 /PRNewswire/ - ESSA ... financial results for the second quarter and three and six ... expressed in Canadian dollars and in accordance with International Financial ... ESSA recorded a net loss of $5.9 million ($0.35 ... 2015 (Q2-2015), compared to a net loss of $0.4 million ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14The Association for the Advancement of Wound Care Educates the Public 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... Presented at the 132nd Annual Meeting of the American Neurological ... Association in ... presented results from two,Phase III pivotal trials and one open-label ... restless legs,syndrome (RLS). These rotigotine data showed significant drops in ...
... Boehringer Ingelheim,Pharmaceuticals, Inc. today announced that ... full (traditional) approval of Aptivus(R),(tipranavir) capsules. The ... 2005; accelerated approval is a regulatory process ... or life-threatening illnesses. The full,approval of APTIVUS ...
Cached Medicine Technology:Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 2Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 3Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 4Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 5Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 2Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 3Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 4Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 5Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 6Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 7Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 8
(Date:5/29/2015)... 29, 2015 World Patent Marketing, a ... that it has signed a 10 year licensing agreement ... aims to let people learn about any topic and ... , "This is an exciting day for World Patent ... J. Cooper, CEO and Creative Director of World Patent ...
(Date:5/29/2015)... 29, 2015 Mediaplanet has joined forces ... protection”. Skin Health is a cross-platform campaign with ... markets of New York, Los Angeles, and Chicago, the ... Its digital counterpart will reach a national audience through ... more the Skin Health campaign and Colorescience, click ...
(Date:5/29/2015)... Dallas, TX (PRWEB) May 29, 2015 ... H1 2015” provides comprehensive information on the therapeutic ... different types of muscles in the body, leading ... strengthens R&D pipelines by identifying new targets and ... report on H1 2015 pipeline review of Axillary ...
(Date:5/29/2015)... Designed with the versatile athlete in mind, ... all new, exclusive line of supplementation called The 24/7 ... and greatest, high impact, result driven ingredients that have ... 24/7 Series can be used by anyone from bodybuilders ... fitness enthusiasts. There are no stimulant based ingredients that ...
(Date:5/29/2015)... 2015 The annual aesthetic meeting, put on ... held in Montreal from May 14-19th. This global event ... from around the world; dedicating itself exclusively to cosmetic medicine. ... renowned plastic surgeons to attend this year’s meeting. , ... Dr. Vitenas was given the honor of sitting at the ...
Breaking Medicine News(10 mins):Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3
... Corporation,(Nasdaq: DRRX ) announced today that James ... at the SIGnificant Investment Options,in Healthcare conference hosted ... at 2:45 p.m. EST. The conference is being ... York City., (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ), ...
... but significant association , , FRIDAY, Feb. 28 (HealthDay News) ... and taking vitamin E may even heighten the risk, ... supplement-taking habits and lung cancer incidence of almost 78,000 ... period. , "Our study of supplemental multivitamins, vitamin C, ...
... Pitching ... Legend Tommy John, SARASOTA, Fla. ... and retail company focused on providing,hearing aids with state-of-the-art fidelity, price ... Square Mall,(Sarasota) and Gulf View Mall (Port Richey)., Years ago, ...
... Feb. 29 Landauer, Inc. (NYSE:,LDR) announced today that ... of $0.50 per share for the second quarter of ... 2008, to shareholders of record,on March 14, 2008., ... analytical services to determine,occupational and environmental radiation exposure. For ...
... Calif., Feb. 29 Genoptix, Inc.,(Nasdaq: GXDX ), ... stock being offered by certain existing stockholders to,the public ... will not,receive any proceeds from the sale. The offer ... offering is being made through an underwriting syndicate led ...
... Feb. 29 /Xinhua-PRNewswire-FirstCall/ -- Qiao Xing,Mobile Communication Co., Ltd. ... one of China,s leading domestic manufacturers of mobile,handsets through ... launch of its new C7000A cardiograph mobile handset., ... Cardiograph function -- Users will be able to perform ...
Cached Medicine News:Health News:Vitamin E Supplements May Raise Lung Cancer Risk 2Health News:Vitamin E Supplements May Raise Lung Cancer Risk 3Health News:Zounds! - Sarasota and Port Richey 'Hear' New Retail Concept Coming 2Health News:Zounds! - Sarasota and Port Richey 'Hear' New Retail Concept Coming 3Health News:Genoptix Announces Pricing of Secondary Public Offering 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 3
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... provide protection to the exposed airway of the ... making it ideal for active young children as ... heat and moisture recovery, it ensures patient comfort ... filters have ISO standard tapered ends to assure ...
... Seven digital models cover the range from 2ul ... fluently. Volume lock design prevents inadvertent volume ... horizontal grip. Whole pipette is autoclavable at ... is all polypropylene. Suitable for one-handed operation. ...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: